Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region
The use of sipavibart or pemivibart as PrEP for COVID-19 in the region may currently not be effective unless new SARS-CoV-2 variants appear not containing these resistance mutations. Further, new mAbs under development as PrEP for COVID-19 can be effectively used by routinely sequencing SARS-CoV-2 in patients to identify variants and resistance mutations.
Authors
- René Kaden (ORCID: https://orcid.org/0000-0002-2111-9751)
- Navaneethan Palanisamy (ORCID: https://orcid.org/0000-0003-0369-2316)
- Martin Sundqvist (ORCID: https://orcid.org/0000-0001-6532-2586)
- Johan Lindh (ORCID: https://orcid.org/0000-0002-8025-6078)
- Patrik Ellström (ORCID: https://orcid.org/0000-0001-8920-6061)
- Jonathan Haars (ORCID: https://orcid.org/0009-0003-8735-4097)
- Johan Lennerstrand (ORCID: https://orcid.org/0000-0002-1093-0530)
- Paula Mölling (ORCID: https://orcid.org/0009-0000-1143-9105)
- Karin Elfving
- Frans Wallin
- Yin Hong
- Anna-Karin Jonsson
Institutions
- Uppsala University (SE)
- University of Chester (GB)
- Örebro University (SE)
- Science for Life Laboratory (SE)
- Falun Hospital (SE)
- Örebro University Hospital (SE)
- Genomics (United Kingdom) (GB)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1080/23744235.2025.2509011
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40